> Detailanzeige

Schetelig, Johannes; Bornhäuser, Martin; Schmid, Christoph; Hertenstein, Bernd; Schwerdtfeger, Rainer; Martin, Hans; Stelljes, Matthias; Hegenbart, Ute; Schäfer-Eckart, Kerstin; Füssel, Monika; Wiedemann, Barbel; Thiede, Christian; Kienast, Joachim; Baurmann, Herrad; Ganser, Arnold; Kolb, Hans Jochem; Ehninger, Gerhard

Matched Unrelated or Matched Sibling Donors Result in Comparable Survival After Allogeneic Stem-Cell Transplantation in Elderly Patients With Acute Myeloid Leukemia: A Report From the Cooperative German Transplant Study Group

Literatur-
verwaltung

Zur
Merkliste

Lösche von
Merkliste

Per Whatsapp teilen

Schließen

Merkliste



Sie können Bookmarks mittels Listen verwalten, loggen Sie sich dafür bitte in Ihr SLUB Benutzerkonto ein.
  • Medientyp: E-Artikel
  • Titel: Matched Unrelated or Matched Sibling Donors Result in Comparable Survival After Allogeneic Stem-Cell Transplantation in Elderly Patients With Acute Myeloid Leukemia: A Report From the Cooperative German Transplant Study Group
  • Beteiligte: Schetelig, Johannes; Bornhäuser, Martin; Schmid, Christoph; Hertenstein, Bernd; Schwerdtfeger, Rainer; Martin, Hans; Stelljes, Matthias; Hegenbart, Ute; Schäfer-Eckart, Kerstin; Füssel, Monika; Wiedemann, Barbel; Thiede, Christian; Kienast, Joachim; Baurmann, Herrad; Ganser, Arnold; Kolb, Hans Jochem; Ehninger, Gerhard
  • Erschienen: American Society of Clinical Oncology (ASCO), 2008
  • Erschienen in: Journal of Clinical Oncology
  • Sprache: Englisch
  • DOI: 10.1200/jco.2007.15.5184
  • ISSN: 0732-183X; 1527-7755
  • Entstehung:
  • Anmerkungen:
  • Beschreibung: <jats:sec><jats:title>Purpose</jats:title><jats:p> In patients with acute myeloid leukemia (AML), differential indications for matched sibling and unrelated hematopoietic stem-cell transplantation (HCT) are considered, and arbitrary age limits for HCT exist. We sought to determine whether donor type is a prognostic factor in elderly patients in the era of high-resolution DNA-based HLA typing. </jats:p></jats:sec><jats:sec><jats:title>Patients and Methods</jats:title><jats:p> We performed univariate and multivariate analyses of event-free survival (EFS) and overall survival (OS) in patients older than 50 years with standard- or high-risk AML who had received an allogeneic HCT between 1995 and 2005. Available DNA from donors and recipients of unrelated HCT was retyped so that the HLA-A, -B, -C, and -DRB1 alleles could be characterized in detail. Unrelated donors (UDs) were classified as matched (8/8), possibly matched (matched, but incomplete information), partially matched (one mismatch), or poorly matched (two or more mismatches) according to the final typing results. </jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p> Data from 368 patients with a median age of 57 years (range, 50 to 73 years) were included. Multivariate Cox regression analysis revealed that patients’ disease status at HCT (P &lt; .001) and the cytogenetic risk (P &lt; .001) highly significantly predicted EFS and OS. Compared with patients with matched sibling donors, the adjusted relative risk of EFS was 0.7 (95% CI, 0.4 to 1.1) for patients with matched UDs and 1.0 (95% CI, 0.7 to 1.6) for patients with partially matched UDs. </jats:p></jats:sec><jats:sec><jats:title>Conclusion</jats:title><jats:p> Donor type is not a major prognostic factor for HCT in elderly patients with standard- or high-risk AML. </jats:p></jats:sec>
  • Zugangsstatus: Freier Zugang